Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862574 | 0.88 | CYP2C8 (0.41) | CYP2C8PTGDR2KMT2APPARGMAPT | |
| SCHEMBL831554 | 0.86 | CYP2C8 (0.47) | CYP2C8PTGDR2KMT2APPARGMAPT | |
| SCHEMBL831382 | 0.85 | CYP2C8 (0.40) | CYP2C8PTGDR2KMT2APPARGPARG | |
| SCHEMBL832426 | 0.84 | CYP2C8 (0.43) | CYP2C8PTGDR2KMT2AMAPTPARG | |
| SCHEMBL830899 | 0.84 | CYP2C8 (0.45) | CYP2C8PTGDR2KMT2AMAPTTP53 | |
| SCHEMBL862717 | 0.83 | CYP2C8 (0.42) | CYP2C8PTGDR2KMT2APPARG | |
| SCHEMBL832380 | 0.83 | CYP2C8 (0.43) | CYP2C8PTGDR2KMT2AMAPTPARG | |
| SCHEMBL862158 | 0.82 | CYP2C8 (0.41) | CYP2C8PTGDR2KMT2APPARG | |
| SCHEMBL862175 | 0.82 | MAPT (0.41) | CYP2C8PTGDR2KMT2APPARGMAPT | |
| SCHEMBL831326 | 0.82 | CYP2C8 (0.40) | CYP2C8PTGDR2KMT2APPARGLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885PTGDR2 1609/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.